Abstract 167168

Session 3005.1 Late Breaking Developments in Public Health APHA 135th Annual Meeting, Washington, DC 5 November 2007

Extensively Drug Resistant Tuberculosis: An Update

Kenneth G. Castro, M.D. Assistant Surgeon General, USPHS Director, Division of Tuberculosis Elimination National Center for HIV, Hepatitis, STD, and TB Prevention Coordinating Center for Infectious Diseases






Definitions – I


Initial (Primary) resistance

• TB patient's initial *Mycobacterium tuberculosis* population resistant to drug



Acquired (Secondary) resistance

• Drug-resistant *M. tuberculosis* in initial population selected by inappropriate drug use (inadequate *Rx* regimen or non-adherence)



Definitions – II

Multidrug resistant (MDR) TB

 TB patient's *M. tuberculosis* isolate resistant to ≥ isoniazid and rifampin

 Extensively drug resistant (XDR) TB
 MDR with additional resistance to at least a fluororquinolone and one second-line injectable (amikacin, kanamycin, capreomycin)

XDR TB Background

- Anecdotal descriptions of virtually untreatable TB patients with multi-drug resistant *M. tuberculosis* isolates and additional/extensive drug resistance
- Initial reports of XDR-TB, Oct 2005
 - Shah et al.
 36th World Congress on Lung Health *IJTLD 2005;9(Suppl. 1):S77, S258*
- Study proposal Oct 2005; initial publication Mar 2006



Weekly

World TB Day — March 24, 2006

World TB Day is March 24. This annual event commemorates the date in 1882 when Robert Koch announced his discovery of *Mycobacterium tuberculosis*, the bacterium that causes tuberculosis (TB). Worldwide, TB remains one of the leading causes of death from March 24, 2006 / Vol. 55 / No. 11

Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs — Worldwide, 2000–2004

During the 1990s, multidrug-resistant (MDR) tuberculosis (TB), defined as resistance to at least isoniazid and rifampin,

* Defined as cases in persons with TB whose isolates were resistant to isoniazid and rifampin and at least three of the six main classes of SLDs (aminoglycosides, polypeptides, fluoroquinolones, thioamides, cycloserine, and paraaminosalicyclic acid).

Global WHO/IUATLD/CDC Survey*

- Convenience sample (17,690 isolates) submitted to participating international SRL network, 2000-2004
 - 3520 (20%) of isolates MDR TB
 - 347 (2%) of isolates XDR TB
- XDRTB in all regions, more common FSU and Asia (Republic of Korea)
- Denominator information unavailable

* MMWR 2006;55:301-305

KZN Hospital Background*

- 119 patients in TB/ARV integration study
 - 14 deaths
 - 10 (71%) of 14 with MDRTB
 - 6/10 MDRTB resistant to all tested first and second line drugs for TB
 - •INH, RIF, EMB, STR, KANA, CIPRO

Suggestive of probable extensive drug resistant TB in this hospital

* Moll A, Gandhi NR, Pawinski R, Lalloo U, Sturm AW, Zeller K, Andrews J, Friedland G. HIV associated Extensively Drug-Resistant TB (XDR-TB) in Rural KwaZulu-Natal (South Africa MRC Expert Consultation Sept 8, 2006)

KZN Drug Resistant TB Survey Results*

1539 samples tested

544 (35%) Cx+ *M. tuberculosis* 995 (65%) Cx Negative

221(41%) MDRTB

323 (59%) Susceptible

53 (10%) XDRTB (24% of MDRTB)

* Gandhi NR, Moll A, Sturm AW, Pawinski R, Govendar T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet* 2006;368:1575-80

Copyright 2007, Kenneth G. Castro, kgc1@cdc.gov

XDR TB in KZN: Patient Characteristics*		
Characteristic	No. (%)	
No prior TB treatment (n=47)	26 (55)	
Prior hospitalization [last 2 yrs] (n=42)	28 (67)	
Previous TB treatment (n=47)		
Cured or completed	14 (30)	
Failure or default	7(15)	
HIV infection (n=44)	44 (100)	
Dead: includes 15 (34%) on ARVs	52 (98)	
Identical genotype (n=46)	39 (85)	
* Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Fried	lland G.	


* Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet* 2006;368:1575-1580

Profile of Selected HIV-related MDR TB Outbreak Investigations in U.S., 1988–92

	Total	% HIV	%	Median Wks
Hospital	Cases	Infected	Deaths	Dx to Death
Α	65	93	72	7
В	51	100	89	16
С	70	95	77	4
D	29	91	83	4
E	7	14	43	4
F	16	82	82	4
L I	13	100	85	4
J	28	96	93	4
Prison	42	98	79	4


Copyright 2007, Kenneth G. Castro, kgc1@cdc.gov

Reported TB Cases* United States, 1982–2006



Copyright 2007, Kenneth G. Castro, kgc1@cdc.gov

Primary MDR TB United States, 1993–2006*



*Updated as of April 6, 2007.

J.

Note: Based on initial isolates from persons with no prior history of TB. MDR TB defined as resistance to at least isoniazid and rifampin.



XDR TB Cases by State of Residence, United States, 1993–2006* (Provisional Data, Not for Citation)





2

2



NYC 16

New Jersey 3

8

Copyright 2007, Kenneth G. Castro, kgc1@cdc.gov

XDR TB Cases by Origin, United States,1993–1999 vs. 2000–2006* (Provisional Data, Not for Citation)

Origin**	1993-1999	2000-2006		
U.Sborn	17 (65%)	5 (25%)		
Foreign-born	9 (35%)	15 (75%)		
* Based on Initial DST results ** Two cases of unknown origin				



XDR TB Cases by HIV Status, United States,1993–1999 vs. 2000–2006* (Provisional Data, Not for Citation)

HIV Status	1993 – 1999	2000 – 2006
HIV positive	14 (50%)	2 (10%)
HIV negative	4 (14%)	9 (45%)
Unknown	10 (36%)	9 (45%)

* Based on initial DST results





Copyright 2007, Kenneth G. Castro, kgc1@cdc.gov

XDR TB Cases by Fatality, United States,1993–2006* (Provisional Data, Not for Citation)

Dead at diagnosis (2) or during <i>Rx</i> (15)	17 (35%) of 48
Avg. time to death (from start of Rx)	117 days
Median time to death (from start of Rx)	45 days
Range, time to death (from start of <i>Rx</i>)	0 – 984 days

No. dead (cases with known outcome) 17/33 (52%)






* Based on initial DST results

TB Treatment Outcomes, by Selected Drug Resistance Patterns, Latvia, 2000-2003*

□ Cure □ Death □ Default ■ Failed □ HIV+



Copyright 2007, Kenneth G. Castro, kgc1@cdc.gov

MDR, XDR TB: Why be Concerned?

- Treatment requires 18–24 mo (vs 6–8 mo)
- Relapse rates ~30-40% (vs < 5%)</p>
- Higher case fatality
- Prolonged infectiousness
- Adverse events common
- Higher costs (> 100-fold increase)
 - -Avg hospitalization cost for XDR \$477,000



XDR TB as a Global Emerging Threat: Why Now?

- Convergence of factors creating "the perfect storm"
 - -Suboptimal TB control practices
 - -High HIV prevalence
 - -High TB burden
 - Introduction of second-line TB drugs into low and middle income countries

Global 7-point Action Plan to Combat XDR TB

Emphasizes Essentials of Proper TB Control

- 1. Conduct rapid surveys of XDR-TB (determine burden)
- 2. Enhance laboratory capacity (emphasis on rapid DST)
- 3. Improve technical capacity of clinical and public health practitioners to effectively respond to XDR-TB outbreaks and manage patients
- 4. Implement infection control precautions (PLHA focus)
- 5. Increase research support for anti-TB drug development
- 6. Increase research support for rapid diagnostic test development
- 7. Promote universal access to ARVs under joint TB/HIV activities

MRC Consultation, Johannesburg, South Africa. Sept 7, 2006

Acknowledgements

WHO/Stop TB Department

- A. Wright
- E. Jaramillo
- M. Aziz
- M. Zignol
- P. Nunn

FIND

R. O'Brien

TB Controllers, USA

- S. Munsiff (NYC)
- M. Oxtoby (NYS)
- R. Royce (CA)



CDC/DTBE

- P. Cegielski
- C. Wells
- T. Shinnick
- S. Shah (AECOM)
- T. Holtz
- L. Armstrong
- V. Robison
- S. Althomsons
- R. Wallace
- S. Price
- T. Navin
- K. ljaz
- H. Duncan
- D. Ruggiero
- M. Hlavsa
- P.LoBue



WHO/HTM/TB/2007.387

THE GLOBAL PLAN TO STOP TB 2 0 0 6 - 2 0 1 5

Actions for Life towards a world free of tuberculosis

Strategic Plan 2006–2015

- Assess epidemiologic impact of interventions by regions and cost
- 10-yr cost \$56.1 billion (need \$30.8 billion)

The Global MDR-TB & XDR-TB Response Plan 2007-2008

Supplemental Plan \$2.15 billion Emphasis on Basic TB control 7 Action Steps